Clinical and translational advances in ovarian cancer therapy

PA Konstantinopoulos, UA Matulonis - Nature cancer, 2023‏ - nature.com
Ovarian cancer is an aggressive disease that is frequently detected at advanced stages and
is initially very responsive to platinum-based chemotherapy. However, the majority of …

[HTML][HTML] The systemic treatment of recurrent ovarian cancer revisited

T Baert, A Ferrero, J Sehouli, DM O'donnell… - Annals of …, 2021‏ - Elsevier
Highlights•Platinum-based chemotherapy remains the most active treatment for ovarian
cancer.•Platinum should not be withheld after response to last platinum and a treatment-free …

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

SM Domchek, S Postel-Vinay, SA Im, YH Park… - The Lancet …, 2020‏ - thelancet.com
Background Poly (ADP-ribose) polymerase inhibitors combined with immunotherapy have
shown antitumour activity in preclinical studies. We aimed to assess the safety and activity of …

Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study

EJ Lampert, A Zimmer, M Padget… - Clinical Cancer …, 2020‏ - aacrjournals.org
Purpose: Preclinical studies suggest PARP inhibition (PARPi) induces immunostimulatory
micromilieu in ovarian cancer thus complementing activity of immune checkpoint blockade …

Advances in the management of peritoneal malignancies

V Kepenekian, A Bhatt, J Péron, M Alyami… - Nature reviews Clinical …, 2022‏ - nature.com
Peritoneal surface malignancies (PSMs) are usually associated with a poor prognosis.
Nonetheless, in line with advances in the management of most abdominopelvic metastatic …

Mfn2-mediated mitochondrial fusion promotes autophagy and suppresses ovarian cancer progression by reducing ROS through AMPK/mTOR/ERK signaling

R Ashraf, S Kumar - Cellular and Molecular Life Sciences, 2022‏ - Springer
Mitochondrial dynamics are balanced fission and fusion events that regulate mitochondrial
morphology, and alteration in these events results in mitochondrial dysfunction and …

Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group

G Freyer, A Floquet, O Tredan, A Carrot… - Nature …, 2024‏ - nature.com
Most patients with advanced ovarian cancer (AOC) ultimately relapse after platinum-based
chemotherapy. Combining bevacizumab, olaparib, and durvalumab likely drives synergistic …

[HTML][HTML] Immunotherapies and combination strategies for immuno-oncology

C Barbari, T Fontaine, P Parajuli… - International journal of …, 2020‏ - mdpi.com
The advent of novel immunotherapies in the treatment of cancers has dramatically changed
the landscape of the oncology field. Recent developments in checkpoint inhibition therapies …

[HTML][HTML] Therapeutic targeting of DNA damage response in cancer

W Choi, ES Lee - International journal of molecular sciences, 2022‏ - mdpi.com
DNA damage response (DDR) is critical to ensure genome stability, and defects in this
signaling pathway are highly associated with carcinogenesis and tumor progression …

CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer

S Seitz, TF Dreyer, C Stange, K Steiger… - British Journal of …, 2022‏ - nature.com
Background Response to immune checkpoint blockade (ICB) in ovarian cancer remains
disappointing. Several studies have identified the chemokine CXCL9 as a robust …